Alantolactone induces G1 phase arrest and apoptosis of multiple myeloma cells and overcomes bortezomib resistance

Alantolactone selectively suppresses STAT3 activation and exhibits potent anticancer activity in MDA-MB-231 cells

(2015) Jaemoo Chun et al.   CANCER LETTERS

Alantolactone Induces Apoptosis and Cell Cycle Arrest on Lung Squamous Cancer SK-MES-1 Cells

(2015) Peng Zhao et al.   JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY

Alantolactone fromSaussurea lappaExerts Antiinflammatory Effects by Inhibiting Chemokine Production and STAT1 Phosphorylation in TNF-α and IFN-γ-induced in HaCaT cells

(2015) Hye-Sun Lim et al.   PHYTOTHERAPY RESEARCH

Inhibition of mTOR with everolimus and silencing by vascular endothelial cell growth factor-specific siRNA induces synergistic antitumor activity in multiple myeloma cells

(2014) M Koldehoff et al.   CANCER GENE THERAPY

Aspirin inhibits proliferation and induces apoptosis of multiple myeloma cells through regulation of Bcl-2 and Bax and suppression of VEGF

(2014) Jiang-hua Ding et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

HGF, sIL-6R and TGF-β1 Play a Significant Role in the Progression of Multiple Myeloma

(2014) Artur Jurczyszyn et al.   Journal of Cancer

Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-κB inhibition and Bcr/Abl protein deletion

(2013) Wei Wei et al.   APOPTOSIS

Alantolactone inhibits growth of K562/adriamycin cells by downregulating Bcr/Abl and P-glycoprotein expression

(2013) Chunhui Yang et al.   IUBMB LIFE

Alantolactone induces cell apoptosis partially through down-regulation of testes-specific protease 50 expression

(2013) Xu-Guang Mi et al.   TOXICOLOGY LETTERS

Juglanthraquinone C, a novel natural compound derived from Juglans mandshurica Maxim, induces S phase arrest and apoptosis in HepG2 cells

(2012) Yao Yao et al.   APOPTOSIS

Alantolactone suppresses inducible nitric oxide synthase and cyclooxygenase-2 expression by down-regulating NF-κB, MAPK and AP-1 via the MyD88 signaling pathway in LPS-activated RAW 264.7 cells

(2012) Jaemoo Chun et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

The Future of Therapy for Relapsed/Refractory Multiple Myeloma: Emerging Agents and Novel Treatment Strategies

(2012) Philippe Moreau   SEMINARS IN HEMATOLOGY

Biological aspects of angiogenesis in multiple myeloma

(2011) Eléonore Otjacques et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells

(2011) N E Franke et al.   LEUKEMIA

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance

(2010) B. Nair et al.   BLOOD

Role of NF-κB in the skeleton

(2010) Deborah Veis Novack   CELL RESEARCH

Therapeutic approaches for newly diagnosed multiple myeloma patients in the era of novel drugs

(2010) Fortunato Morabito et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

(2009) P. Richardson et al.   BLOOD

Isoalantolactone from Inula helenium Caused Nrf2-Mediated Induction of Detoxifying Enzymes

(2009) Ji Yeon Seo et al.   JOURNAL OF MEDICINAL FOOD

Proteasome inhibitors in the treatment of multiple myeloma

(2009) J J Shah et al.   LEUKEMIA

Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade

(2008) R. Z. Orlowski et al.   CLINICAL CANCER RESEARCH

Mechanisms of proteasome inhibitor action and resistance in cancer

(2008) David J. McConkey et al.   DRUG RESISTANCE UPDATES

The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma

(2008) Philipp Baumann et al.   EXPERIMENTAL CELL RESEARCH